transcarbamylase

trans·car·bam·yl·ase

(trăns′kär-băm′ə-lās′, -lāz′) or trans·car·bam·o·yl·ase (trăns′kär-băm′ō-ə-lās′, -lāz′)
n.
Any of various enzymes that catalyze the transfer of carbamyl groups from one molecule to another. Also called carbamyltransferase.
References in periodicals archive ?
Mutations and polymorphisms in the human ornithine transcarbamylase gene.
Messenger RNA pipeline programs include thrombopoietin (LUNAR-TPO) for the management of thrombocytopenia, ornithine transcarbamylase (LUNAR-OTC) for the treatment of ornithine transcarbamylase deficiency, hepcidin (LUNAR-HPN) for the treatment of iron disorders, and cystic fibrosis transmembrane conductance regulator (LUNAR-CF) for the treatment of cystic fibrosis
As a baby she had been diagnosed with ornithine transcarbamylase (OTC) deficiency, which means her body builds up dangerous levels of ammonia and need constant monitoring.
Billy was born with a condition called ornithine transcarbamylase deficiency.
Through this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute a new therapeutic option for patients suffering from Urea Cycle Disorders (UCD), a group of rare diseases involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate sythetase.
These biochemical findings were consistent with ornithine transcarbamylase (OTC) deficiency.
By far the most common of the urea cycle defects is the X-linked recessive disorder, ornithine transcarbamylase deficiency (OTC).
The metabolic diseases are divided into those associated with structural damage to the liver (Wilson's, alpha-1 antitrypsin) and those in which the liver is structurally normal and LT is required to replace a life-threatening enzyme deficiency (Crigler-Najjar syndrome, ornithine transcarbamylase deficiency, or hyperoxaluria type 1).
1] The carcinogenic substances currently being investigated include nitrosamine, reactive oxygen species, epidermal growth factor, transforming growth factor, cyclo-oxygenase, mucin and ornithine transcarbamylase.
Clinical and laboratory observations of thirty-two Japanese male patients with ornithine transcarbamylase deficiency.
In 1999 Jesse Gelsinger reached his eighteenth birthday after surviving for sixteen years with a rare metabolic liver condition called "ornithine transcarbamylase (OTC) deficiency.
Jesse, who was eighteen years old, was participating in a phase I safety study of a gene transfer therapy for ornithine transcarbamylase deficiency (OTCD), a rare metabolic condition.

Full browser ?